Aesthetic Medical International Holdings Group Limited (Nasdaq:
AIH) (the “Company” or “AIH”), a leading provider of aesthetic
medical services in China, announced its unaudited financial
results for the six months ended June 30, 2023.
Mr. ZHANG Chen, the Chairman of the
Company, commented, “On August 16, 2023, I was honored to
be elected as the Chairman of AIH. This was a significant date for
us as it marked the successful closure of a series of equity
transactions that were initiated on July 20, 2022. As
Chairman, I am committed to working closely with our team to
ensure that we continue to execute our new strategic initiatives
and deliver value to our stakeholders. I am excited to lead AIH
during this transformative period and am confident that we will
achieve success together. In the first half of 2023, we observed
the results of our informatization and digitization efforts. With
information technology as our foundation and refined management as
our ultimate goal, we have taken the first step towards data
accuracy across various departments, which enabled real-time
observation and analysis of data from each module in the actual
operation of the Company. Our informational and digital
transformation initiative aims to identify and address issues in
real-time by analyzing data, improving efficiency, and making
data-driven decisions.”
Mr. ZHANG Chen continued, “Moving forward,
we plan to build upon our informational and digital infrastructure
and continue to strengthen our customer relationship management
department. By improving the accuracy and segmentation of our data
analysis, we can better understand our customers' needs and
preferences, and tailor our products and services to meet those
needs. We also plan to prioritize talent training, both internally
and externally, by implementing a comprehensive training system
that emphasizes skill development and career advancement. In
addition, we are committed to the standardization of energy-based
treatments as the core of our future brand expansion. Our expansion
efforts will be centered around a consumer-oriented business plan
that emphasizes our commitment to customer satisfaction. Finally,
we understand the importance of remaining grounded and building a
strong foundation as we navigate the current economic recovery.
With these efforts, I am confident that AIH can establish
itself as an outstanding enterprise in the future.”
First Half 2023 Financial Highlights
• |
Total revenue was RMB319.3 million (USD44.0 million), a decrease of
5.7% from RMB338.6 million in the first half of 2022. |
• |
Gross profit was RMB151.8 million (USD20.9 million), a decrease of
19.6% from RMB188.7 million in the first half of 2022. |
• |
Selling, general and administrative ("SG&A") expenses together
were RMB159.8 million (USD22.0 million), a decrease of 9.9% from
RMB177.3 million in the first half of 2022, and SG&A expenses
as a percentage of revenue decreased from 52.4% to 50.0%. |
• |
EBITDA1 was RMB22.4 million (USD3.1 million), compared with RMB44.8
million in the first half of 2022. |
• |
Adjusted EBITDA1 was RMB26.7 million (USD3.7 million), decreased
from RMB58.0 million in the first half of 2022. |
1 EBITDA and adjusted EBITDA are not prepared in
accordance with International Financial Reporting Standards as
issued by the International Accounting Standard Board, or IFRS. For
more information regarding non-IFRS financials, please refer to
“Non-IFRS Financial Measures” and “Reconciliations of IFRS and
Non-IFRS Results” appearing elsewhere in this press release.
First Half 2023 Operational Highlights
New and repeat customers
|
|
For the Six Months Ended June 30, |
|
|
|
2022 |
|
|
2023 |
|
|
|
|
|
|
Number |
|
|
% of Total |
|
|
Number |
|
|
% of Total |
|
|
% Change |
|
New Customers |
|
|
22,284 |
|
|
|
20.1 |
% |
|
|
32,685 |
|
|
|
31.4 |
% |
|
|
46.7 |
% |
Repeat Customers |
|
|
88,791 |
|
|
|
79.9 |
% |
|
|
71,488 |
|
|
|
68.6 |
% |
|
|
-19.5 |
% |
Total Active Customers |
|
|
111,075 |
|
|
|
100.0 |
% |
|
|
104,173 |
|
|
|
100.0 |
% |
|
|
-6.2 |
% |
• |
As a result of the divestment of treatment centers and the
temporary closing of treatment centers in January 2023, the
Company recorded a decrease of 6.2% year-on-year in the total
active customers. |
Number of aesthetic medical treatment cases
|
|
For the Six Months Ended June 30, |
|
|
|
2022 |
|
|
2023 |
|
|
|
|
|
|
Number |
|
|
% of Total |
|
|
Number |
|
|
% of Total |
|
|
% Change |
|
Energy-based Treatments |
|
|
207,581 |
|
|
|
71.9 |
% |
|
|
177,603 |
|
|
|
69.3 |
% |
|
|
-14.4 |
% |
Minimally Invasive Aesthetic
Treatments |
|
|
51,728 |
|
|
|
17.9 |
% |
|
|
43,414 |
|
|
|
16.9 |
% |
|
|
-16.1 |
% |
Surgical Treatments |
|
|
16,174 |
|
|
|
5.6 |
% |
|
|
22,054 |
|
|
|
8.6 |
% |
|
|
36.4 |
% |
General healthcare services
and other aesthetic medical services |
|
|
13,034 |
|
|
|
4.5 |
% |
|
|
13,378 |
|
|
|
5.2 |
% |
|
|
2.6 |
% |
Total number of treatment
cases |
|
|
288,517 |
|
|
|
100.0 |
% |
|
|
256,449 |
|
|
|
100.0 |
% |
|
|
-11.1 |
% |
• |
As a result of the divestment of treatment centers and the
temporary closing of treatment centers in January 2023, the
Company recorded a decrease in the number of treatment cases of
11.1% year-on-year. |
• |
Total number of non-surgical aesthetic medical treatments as a
percentage of the total number of aesthetic treatments decreased by
3.6 percentage points. |
Average spending per customer
• |
Average spending per customer increased by 6.0% from RMB1,174 in
the first half of 2022 to RMB1,245 in the first half of 2023,
primarily driven by the strategic decision to remove most of the
low-price treatment promotions from our service offerings. |
First Half 2023 Unaudited Financial Results
|
|
For the Six Months Ended June 30, |
|
(RMB
millions, except per share data and percentages) |
|
2022 |
|
|
2023 |
|
|
% Change |
|
Revenue |
|
|
338.6 |
|
|
|
319.3 |
|
|
|
-5.7 |
% |
Non-surgical aesthetic medical services |
|
|
237.1 |
|
|
|
229.9 |
|
|
|
-3.0 |
% |
Minimally invasive aesthetic treatments |
|
|
103.8 |
|
|
|
114.2 |
|
|
|
10.0 |
% |
Energy-based treatments |
|
|
133.3 |
|
|
|
115.7 |
|
|
|
-13.2 |
% |
Surgical aesthetic medical services |
|
|
73.6 |
|
|
|
57.8 |
|
|
|
-21.5 |
% |
General healthcare services and other aesthetic medical
services |
|
|
27.9 |
|
|
|
31.6 |
|
|
|
13.3 |
% |
Gross profit |
|
|
188.7 |
|
|
|
151.8 |
|
|
|
-19.6 |
% |
Gross margin |
|
|
55.7 |
% |
|
|
47.5 |
% |
|
|
-8.2 |
p.p.2 |
(Loss) for the period |
|
|
(3.7 |
) |
|
|
(11.4 |
) |
|
|
N.M. |
4 |
(Loss) margin |
|
|
(1.1 |
)% |
|
|
(3.6 |
)% |
|
|
N.M. |
4 |
EBITDA3 |
|
|
44.8 |
|
|
|
22.4 |
|
|
|
-50.1 |
% |
Adjusted EBITDA3 |
|
|
58.0 |
|
|
|
26.7 |
|
|
|
-54.0 |
% |
Adjusted EBITDA margin |
|
|
17.1 |
% |
|
|
8.4 |
% |
|
|
-8.7 |
p.p.2 |
Adjusted
profit/(loss)3 |
|
|
9.5 |
|
|
|
(7.0 |
) |
|
|
N.M. |
4 |
Adjusted profit/(loss)
margin |
|
|
2.8 |
% |
|
|
(2.2 |
)% |
|
|
N.M. |
4 |
Basic (loss) per share |
|
|
(0.07 |
) |
|
|
(0.08 |
) |
|
|
-14.3 |
% |
Diluted (loss) per share |
|
|
(0.07 |
) |
|
|
(0.08 |
) |
|
|
-14.3 |
% |
Notes:2 p.p. represents percentage points3 Refer to below
“Non-IFRS Financial Measures”4 N.M. represents not meaningful
Revenue
Total revenue was RMB319.3 million (USD44.0
million), representing a decrease of 5.7% from RMB338.6 million in
the first half of 2022, primarily attributable to the divestment of
underperforming assets in 2022 as well as the temporary closing of
treatment centers in January 2023.
Cost of sales and services rendered
Cost of sales and services rendered was RMB167.5
million (USD23.1 million), representing an increase of 11.7% from
RMB149.9 million in the first half of 2022.
Gross profit
Gross profit was RMB151.8 million (USD20.9
million), representing a decrease of 19.6% from RMB188.7 million in
the first half of 2022. Gross profit margin was 47.5%, a decrease
of 8.2 percentage points from 55.7% in the first half of 2022. The
decrease was attributable to the temporary closing of treatment
centers in January 2023.
Selling expenses
Selling expenses were RMB105.1 million (USD14.5
million), representing 32.9% of the Company’s total revenue in the
first half of 2023, compared with RMB111.7 million in the first
half of 2022, which represented 33.0% of the Company’s total
revenue of the first half of 2022. Selling expenses as of revenue
decreased by 0.1 percentage points year-on-year. The reduction in
the selling expenses and its contribution was mainly a result of
the Company's strategic reduction of online advertising budgets, as
well as the divestment of underperforming assets in 2022.
General and administrative
expenses
General and administrative expenses were RMB54.7
million (USD7.5 million), representing a decrease of 16.6% from
RMB65.6 million in the first half of 2022, primarily due to the
divestment of underperforming assets in 2022 and optimization of
the organizational structure and management capacity.
Other gains/(losses), net
Other gains/(losses), net was a loss of RMB3.9
million (USD0.5 million), compared with a profit of RMB1.0 million
in the first half of 2022, primarily due to the disposal of one of
our subsidiaries.
Loss for the period
As a result of the foregoing, the Company
recorded a loss of RMB11.4 million (USD1.6 million) for the first
half of 2023, compared with a loss of RMB3.7 million in the first
half of 2022. Basic and diluted loss per share were both loss of
RMB 0.08 (loss of USD0.01 per share) in the first half of 2023,
compared with basic and diluted loss per share of RMB0.07 in the
first half of 2022.
Certain Non-IFRS items5
EBITDA for the first half of 2023 was RMB22.4
million (USD3.1 million), compared with RMB44.8 million in the
first half of 2022.
Adjusted EBITDA for the first half of 2023 was
RMB26.7 million (USD3.7 million), compared with RMB58.0 million in
the first half of 2022.
Adjusted profit/(loss) after tax for the first
half of 2023 was a loss of RMB7.0 million (USD1.0 million),
compared with RMB9.5 million in the first half of 2022.
5 EBITDA, adjusted EBITDA, and adjusted
profit/(loss) are not prepared in accordance with International
Financial Reporting Standards as issued by the International
Accounting Standard Board, or IFRS. For more information regarding
non-IFRS financials, please refer to “Non-IFRS Financial Measures”
and “Reconciliations of IFRS and Non-IFRS Results” appearing
elsewhere in this press release.
Cash and cash equivalents
Cash and cash equivalents amounted to RMB87.9
million (USD12.1 million) as of June 30, 2023, compared with
RMB26.2 million as of June 30, 2022. The increase in cash and
cash equivalents was primarily attributable to the private
placement offerings to Hawyu (HK) Limited and MY Universe (HK)
Limited.
Liquidity and capital resources
The Company had a net current asset of a loss of
RMB297.5 million (USD41.0 million) as of June 30, 2023, which
included current borrowings of RMB111.9 million.
Recent Developments
Renovation of Shenzhen Pengcheng Hospital and
Safe Beauty Initiative Ceremony
The renovation of Shenzhen Pengcheng Hospital's
facade, lobby, and energy-based department was completed in
July 2023. On the 28th of the same month, the “2023 Aesthetic
Medical Industry Safe Beauty Initiative Ceremony” was successfully
held. Ms. Hu Qing, Chief Operating Officer of the Company,
delivered a speech at the ceremony. She stated that Shenzhen
Pengcheng Hospital, as the founding hospital of AIH, has always
been at the forefront of the industry and has demonstrative
significance in the industry. It is believed that Shenzhen
Pengcheng Hospital will continue to prioritize “Safe Beauty” and
will constantly improve and innovate to create a new industry
service model. The hospital aims to provide more convenient,
high-end, and high-quality aesthetic experiences. Ms. Hu
emphasized that the Shenzhen Pengcheng Aesthetic Medical Beauty
brand upgrade is part of AIH's upgrading, marking an important step
towards the modernization of the aesthetic medical industry.
Significant Efforts Made in Medical Safety
Control
During the first half of 2023, the Company has
made significant efforts in terms of medical safety control.
Firstly, AIH has released the first issue of its medical management
newsletter, which includes regulations for the practice behavior of
institutions and physicians, strengthening the ability to deal with
medical emergencies, and improving the management of prophylactic
antimicrobial drugs used in surgery. Additionally, AIH has
strengthened the safety management of anesthesia for general
anesthesia surgery and standardized the content of medical
documents. Secondly, AIH has developed operational capacity
assessment standards for surgical, minimally invasive, and
energy-based treatments for the recruitment of new physicians.
Finally, AIH has established a monthly medical institution
operation reporting system to better understand the operations of
each medical institution under the Company in a timely manner.
Successful Closing of Share Transfer, Conversion
of Convertible Note and Issue of Warrants
Reference is made to the press release of the
Company filed with the Securities and Exchange Commission (the
“SEC”) on July 20, 2022 and form 6-K of the Company filed with
the SEC on February 16, 2023 and August 17, 2023
(collectively, “Previous Disclosure”) in relation to, among other,
entry into a share purchase agreement, a subscription agreement, a
shareholders’ agreement and a cooperation agreement. All
capitalized terms not otherwise defined herein shall have the
meanings ascribed to them in the Previous Disclosure. On
August 16, 2023, the Company has closed its previously
announced (i) Share Transfer of an aggregate of 21,321,962
ordinary shares of the Company from Seefar, Jubilee, and Pengai
Hospital Management Corporation to Wanda; (ii) issue of a
total number of 12,088,808 ordinary shares of the Company to ADV at
a conversion price of US dollars equivalent of RMB4.203 per
ordinary share; and (iii) issue and allotment of 4,655,386 and
6,423,983 warrants to Seefar and Wanda respectively, which can be
converted into one ordinary share per warrant upon exercise.
Exchange Rate
This press release contains translations of
certain Renminbi (RMB) amounts into U.S. dollars (USD) solely for
the convenience of the reader. Unless otherwise specified, all
translations of Renminbi amounts into U.S. dollar amounts in this
press release are made at RMB7.2513 to USD1.0, which was the U.S.
dollars middle rate announced by the Board of Governors of the
Federal Reserve System of the United States on June 30,
2023.
Non-IFRS Financial Measures
EBITDA represents profit before income tax,
adjusted to exclude finance costs and amortization and
depreciation. Adjusted EBITDA represents EBITDA, adjusted to
exclude professional fee, share-based payment, loss on disposal of
subsidiaries.
Adjusted profit/(loss) represents profit/(loss)
for the period, adjusted to exclude professional fee, share-based
payment, loss on disposal of subsidiaries.
EBITDA, adjusted EBITDA and adjusted
profit/(loss) are non-IFRS financial measures. You should not
consider EBITDA, adjusted EBITDA and adjusted profit/(loss) as a
substitute for or superior to net income prepared in accordance
with IFRS. Furthermore, because non-IFRS measures are not
determined in accordance with IFRS, they are susceptible to varying
calculations and may not be comparable to other similarly titled
measures presented by other companies. You are encouraged to review
the Company’s financial information in its entirety and not rely on
a single financial measure.
The Company presents EBITDA, adjusted EBITDA and
adjusted profit/(loss) as supplemental performance measures because
it believes that such measures provide useful information to the
investors in understanding and evaluating the Company’s results of
operations, and facilitate operating performance comparisons from
period to period and company to company.
About Aesthetic Medical International Holdings Group
Limited
AIH, known as “Peng’ai” in China, is a leading
provider of aesthetic medical services in China. AIH operates
through treatment centers that are spread across major cities in
mainland China, with a major focus on the Guangdong-Hong Kong-Macau
Greater Bay area and the Yangtze River Delta area. Leveraging over
20 years of clinical experience, AIH provides one-stop aesthetic
service offerings, including surgical aesthetic treatments,
non-surgical aesthetic treatments, general medical services, and
other aesthetic services. For more information regarding the
Company, please visit https://ir.aihgroup.net/.
Cautionary Statements
This press release contains “forward-looking
statements.” These statements are made under the “safe harbor”
provisions of the U.S. Private Securities Litigation Reform Act of
1995. These forward-looking statements can be identified by
terminology such as “will”, “expects”, “anticipates”, “aims”,
“future”, “intends”, “plans”, “believes”, “estimates”, “likely to”
and similar statements. Statements that are not historical facts,
including statements about the Company’s beliefs, plans and
expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties. These risks
and uncertainties and others that relate to the Company’s business
and financial condition are detailed from time to time in the
Company’s SEC filings, and could cause the actual results to differ
materially from those contained in any forward-looking statement.
These forward-looking statements are made only as of the date
indicated, and the Company undertakes no obligation to update or
revise the information contained in any forward-looking statements,
except as required under applicable law.
Investor Relations Contacts
For investor and media inquiries, please
contact:Aesthetic Medical International Holdings Group
LimitedEmail: ir@pengai.com.cnWebsite:
https://ir.aihgroup.net
AESTHETIC MEDICAL INTERNATIONAL HOLDINGS GROUP
LIMITED |
CONSOLIDATED BALANCE SHEETS |
|
|
|
30 June |
|
|
30 June |
|
|
30 June |
|
|
|
2022 |
|
|
2023 |
|
|
2023 |
|
|
|
RMB’000 |
|
|
RMB’000 |
|
|
USD’000 |
|
ASSETS |
|
|
|
|
|
|
|
|
|
|
|
|
Non-current
assets |
|
|
|
|
|
|
|
|
|
|
|
|
Property, plant and
equipment |
|
|
361,887 |
|
|
|
303,848 |
|
|
|
41,903 |
|
Investment properties |
|
|
- |
|
|
|
23,065 |
|
|
|
3,181 |
|
Intangible assets |
|
|
38,878 |
|
|
|
36,500 |
|
|
|
5,034 |
|
Investments accounted for
using the equity method |
|
|
5,764 |
|
|
|
- |
|
|
|
- |
|
Prepayments and deposits |
|
|
18,737 |
|
|
|
11,434 |
|
|
|
1,577 |
|
Deferred income tax
assets |
|
|
44,299 |
|
|
|
69,482 |
|
|
|
9,581 |
|
|
|
|
469,565 |
|
|
|
444,329 |
|
|
|
61,276 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
assets |
|
|
|
|
|
|
|
|
|
|
|
|
Inventories |
|
|
28,809 |
|
|
|
23,710 |
|
|
|
3,270 |
|
Trade receivables |
|
|
6,075 |
|
|
|
7,379 |
|
|
|
1,018 |
|
Other receivables, deposits
and prepayments |
|
|
35,194 |
|
|
|
33,121 |
|
|
|
4,568 |
|
Amounts due from related
parties |
|
|
3,537 |
|
|
|
2,873 |
|
|
|
395 |
|
Restricted cash |
|
|
- |
|
|
|
2,049 |
|
|
|
283 |
|
Asset held-for-sale |
|
|
- |
|
|
|
1,083 |
|
|
|
149 |
|
Cash and cash equivalents |
|
|
26,228 |
|
|
|
87,877 |
|
|
|
12,119 |
|
|
|
|
99,843 |
|
|
|
158,092 |
|
|
|
21,802 |
|
Total
assets |
|
|
569,408 |
|
|
|
602,421 |
|
|
|
83,078 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EQUITY AND
LIABILITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Equity attributable to
owners of the Company |
|
|
|
|
|
|
|
|
|
|
|
|
Share capital |
|
|
469 |
|
|
|
873 |
|
|
|
120 |
|
Treasury shares |
|
|
(2023 |
) |
|
|
(2023 |
) |
|
|
(279 |
) |
Accumulated losses |
|
|
(1,064,524 |
) |
|
|
(1,150,846 |
) |
|
|
(158,709 |
) |
Other reserves |
|
|
914,864 |
|
|
|
1,197,885 |
|
|
|
165,196 |
|
|
|
|
(151,214 |
) |
|
|
45,889 |
|
|
|
6,328 |
|
Non-controlling
interests |
|
|
(29,479 |
) |
|
|
(14,025 |
) |
|
|
(1,934 |
) |
Total
equity |
|
|
(180,693 |
) |
|
|
31,864 |
|
|
|
4,394 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AESTHETIC MEDICAL INTERNATIONAL HOLDINGS GROUP
LIMITED |
CONSOLIDATED BALANCE SHEETS (CONTINUED) |
|
|
|
30 June |
|
|
30 June |
|
|
30 June |
|
|
|
2022 |
|
|
2023 |
|
|
2023 |
|
|
|
RMB’000 |
|
|
RMB’000 |
|
|
USD’000 |
|
LIABILITIES |
|
|
|
|
|
|
|
|
|
|
|
|
Non-current
liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
Borrowings |
|
|
72,950 |
|
|
|
29,545 |
|
|
|
4,074 |
|
Lease liabilities |
|
|
112,980 |
|
|
|
85,450 |
|
|
|
11,784 |
|
Convertible note |
|
|
38,059 |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
223,989 |
|
|
|
114,995 |
|
|
|
15,858 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current
liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
Trade payables |
|
|
44,438 |
|
|
|
36,414 |
|
|
|
5,022 |
|
Accruals, other payables and
provisions |
|
|
75,936 |
|
|
|
36,857 |
|
|
|
5,084 |
|
Contingent consideration and
consideration payable |
|
|
6,850 |
|
|
|
3,592 |
|
|
|
495 |
|
Amounts due to related
parties |
|
|
473 |
|
|
|
- |
|
|
|
- |
|
Contract liabilities |
|
|
193,209 |
|
|
|
165,390 |
|
|
|
22,808 |
|
Borrowings |
|
|
167,232 |
|
|
|
111,937 |
|
|
|
15,437 |
|
Lease liabilities |
|
|
29,175 |
|
|
|
27,391 |
|
|
|
3,777 |
|
Current income tax
liabilities |
|
|
8,799 |
|
|
|
9,416 |
|
|
|
1,299 |
|
Convertible note |
|
|
- |
|
|
|
64,565 |
|
|
|
8,904 |
|
|
|
|
526,112 |
|
|
|
455,562 |
|
|
|
62,826 |
|
Total
liabilities |
|
|
750,101 |
|
|
|
570,557 |
|
|
|
78,684 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total equity and
liabilities |
|
|
569,408 |
|
|
|
602,421 |
|
|
|
83,078 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AESTHETIC MEDICAL INTERNATIONAL HOLDINGS GROUP
LIMITED |
CONSOLIDATED STATEMENTS OF COMPREHENSIVE
INCOME |
|
|
|
30 June |
|
|
30 June |
|
|
30 June |
|
|
|
2022 |
|
|
2023 |
|
|
2023 |
|
|
|
RMB’000 |
|
|
RMB’000 |
|
|
USD’000 |
|
Revenue |
|
|
338,594 |
|
|
|
319,303 |
|
|
|
44,034 |
|
Cost of sales and services
rendered |
|
|
(149,898 |
) |
|
|
(167,547 |
) |
|
|
(23,106 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit |
|
|
188,696 |
|
|
|
151,756 |
|
|
|
20,928 |
|
Selling expenses |
|
|
(111,692 |
) |
|
|
(105,113 |
) |
|
|
(14,496 |
) |
General and administrative
expenses |
|
|
(65,643 |
) |
|
|
(54,668 |
) |
|
|
(7,539 |
) |
Finance income |
|
|
78 |
|
|
|
78 |
|
|
|
11 |
|
Finance costs |
|
|
(17,003 |
) |
|
|
(9,650 |
) |
|
|
(1,331 |
) |
Other gains/(losses), net |
|
|
998 |
|
|
|
(3,878 |
) |
|
|
(535 |
) |
(Loss) before income
tax |
|
|
(4,566 |
) |
|
|
(21,475 |
) |
|
|
(2,962 |
) |
Income tax credit |
|
|
820 |
|
|
|
10,124 |
|
|
|
1,397 |
|
(Loss) for the
period |
|
|
(3,746 |
) |
|
|
(11,351 |
) |
|
|
(1,565 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive
(loss)/income for the period |
|
|
(3,746 |
) |
|
|
(11,351 |
) |
|
|
(1,565 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss)/profit
attributable to: |
|
|
|
|
|
|
|
|
|
|
|
|
Owners of the Company |
|
|
(4,621 |
) |
|
|
(10,078 |
) |
|
|
(1,390 |
) |
Non-controlling interests |
|
|
875 |
|
|
|
(1,273 |
) |
|
|
(175 |
) |
(Loss)/profit for the
period |
|
|
(3,746 |
) |
|
|
(11,351 |
) |
|
|
(1,565 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
AESTHETIC MEDICAL INTERNATIONAL HOLDINGS GROUP
LIMITED |
|
CONSOLIDATED STATEMENTS OF COMPREHENSIVE
INCOME |
|
|
|
|
|
30 June |
|
|
30 June |
|
|
30 June |
|
|
|
2022 |
|
|
2023 |
|
|
2023 |
|
|
|
RMB’000 |
|
|
RMB’000 |
|
|
USD’000 |
|
(Loss)/earnings per share for (loss)/profit attributable to
owners of the Company (in RMB per share) |
|
|
|
|
|
|
|
|
|
|
|
|
—Basic |
|
|
(0.07 |
) |
|
|
(0.08 |
) |
|
|
(0.01 |
) |
—Diluted |
|
|
(0.07 |
) |
|
|
(0.08 |
) |
|
|
(0.01 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive
(loss)/income attributable to: |
|
|
|
|
|
|
|
|
|
|
|
|
Owners of the Company |
|
|
(4,621 |
) |
|
|
(10,078 |
) |
|
|
(1,390 |
) |
Non-controlling interests |
|
|
875 |
|
|
|
(1,273 |
) |
|
|
(175 |
) |
Total comprehensive
(loss)/income for the year |
|
|
(3,746 |
) |
|
|
(11,351 |
) |
|
|
(1,565 |
) |
EBITDA |
|
|
44,834 |
|
|
|
22,361 |
|
|
|
3,084 |
|
Adjusted EBITDA |
|
|
58,033 |
|
|
|
26,728 |
|
|
|
3,686 |
|
Adjusted profit/(loss) |
|
|
9,453 |
|
|
|
(6,984 |
) |
|
|
(963 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
AESTHETIC
MEDICAL INTERNATIONAL HOLDINGS GROUP LIMITED |
|
RECONCILIATIONS OF IFRS AND NON-IFRS RESULTS |
|
|
|
|
|
EBITDA and Adjusted EBITDA |
|
For the Six Months Ended June 30, |
|
|
|
2022 |
|
|
2023 |
|
|
2023 |
|
|
|
RMB’000 |
|
|
RMB’000 |
|
|
USD’000 |
|
(Loss)/profit before income tax for the period |
|
|
(4,566 |
) |
|
|
(21,475 |
) |
|
|
(2,962 |
) |
Adjustments |
|
|
|
|
|
|
|
|
|
|
|
|
+ Finance costs |
|
|
17,003 |
|
|
|
9,650 |
|
|
|
1,331 |
|
+ Amortization and
depreciation |
|
|
32,397 |
|
|
|
34,186 |
|
|
|
4,715 |
|
EBITDA |
|
|
44,834 |
|
|
|
22,361 |
|
|
|
3,084 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
+ Professional fees |
|
|
2,736 |
|
|
|
1,476 |
|
|
|
203 |
|
+ Share-based compensation
expense |
|
|
10,463 |
|
|
|
|
|
|
|
|
|
+ Loss on disposal of
subsidiaries |
|
|
|
|
|
|
2,891 |
|
|
|
399 |
|
Adjusted
EBITDA |
|
|
58,033 |
|
|
|
26,728 |
|
|
|
3,686 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AESTHETIC
MEDICAL INTERNATIONAL HOLDINGS GROUP
LIMITED |
|
RECONCILIATIONS OF IFRS AND NON-IFRS RESULTS
(CONTINUED) |
|
|
|
Adjusted Profit/(Loss) |
|
For the Six Months Ended June 30, |
|
|
|
2022 |
|
|
2023 |
|
|
2023 |
|
|
|
RMB’000 |
|
|
RMB’000 |
|
|
USD’000 |
|
(Loss)/profit for the period |
|
|
(3,746 |
) |
|
|
(11,351 |
) |
|
|
(1,565 |
) |
Adjustments |
|
|
|
|
|
|
|
|
|
|
|
|
+ Professional fees |
|
|
2,736 |
|
|
|
1,476 |
|
|
|
203 |
|
+ Share-based compensation
expense |
|
|
10,463 |
|
|
|
|
|
|
|
|
|
+ Loss on disposal of
subsidiaries |
|
|
|
|
|
|
2,891 |
|
|
|
399 |
|
Adjusted
profit/(loss) |
|
|
9,453 |
|
|
|
(6,984 |
) |
|
|
(963 |
) |
Aesthetic Medical (NASDAQ:AIH)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Aesthetic Medical (NASDAQ:AIH)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024